A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

Trial Profile

A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Anagrelide (Primary)
  • Indications Embolism and thrombosis; Essential thrombocythaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 02 May 2016 Primary endpoints updated due to which trial focus changed from AR to Tu and AR.
    • 17 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top